Advaxis, Inc. (NASDAQ:ADXS) target price increased to $19.00, issued a ratings update today by Cantor Fitzgerald
- Updated: November 29, 2016
Boasting a price of $8.56, Advaxis, Inc. (NASDAQ:ADXS) traded -3.82% lower on the day. With the last stock price close down -13.09% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same period. ADXS has recorded a 50-day average of $9.24 and a two hundred day average of $9.85. Trade Volume was up over the average, with 825,315 shares of ADXS changing hands over the typical 783,042
In a report released on 11/29/2016 Cantor Fitzgerald increased the stock price target of Advaxis, Inc. (NASDAQ:ADXS) to $19.00 reporting a potential upside of 1.22%.
On 09/22/2015, Barclays released a statement for Advaxis, Inc. (NASDAQ:ADXS) bumped up the target price from $0.00 to $40.00 that suggested an upside of 1.50%.
Recent Performance Chart
Advaxis, Inc. has with a 52 week low of $5.21 and a 52 week high of $16.30 and has a market capitalization of $0.
Brief Synopsis On Advaxis, Inc. (NASDAQ:ADXS)
Advaxis, Inc. is a clinical-stage biotechnology company. The Company's immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies. The Company's immunotherapy candidates include Axalimogene filolisbac, ADXS-PSA and ADXS-HER2. Axalimogene filolisbac (ADXS-HPV) is a lead Lm-LLO immunotherapy product candidate for the treatment of human papilloma virus (HPV) associated cancers. ADXS-PSA is an Lm-LLO immunotherapy product candidate designed to target the Prostate Specific Antigen (PSA) associated with prostate cancer. ADXS-HER2 is an Lm-LLO immunotherapy product candidate designed for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) expressing cancers, including human and canine osteosarcoma, breast, gastric and other cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.